• Is Adrenomedullin a new, safe and useful biomarker of pulmonary embolism in the clinical routine?
• Is there any connection in the measurable amount of Adrenomedullin and the severity of pulmonary embolism?
• Is Adrenomedullin a useful biomarker in the clinical practice to decide the indication of thrombolytic treatment in the medium high risk pulmonary embolism patientgroup?